A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy (RESILIENT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05337553 |
Recruitment Status :
Active, not recruiting
First Posted : April 20, 2022
Last Update Posted : November 7, 2023
|
Sponsor:
Biohaven Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Biohaven Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | January 2025 |
Estimated Study Completion Date : | January 2025 |